2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Madhya Pradesh government approves Rs 1,295 crore fo...
India`s steel exports surge 29.1 per cent amid risin...
India`s defence production jumped 174 pc to Rs 1.54 ...
The Evolution of Global Fashion Weeks (Paris, Milan,...
DII Holdings Surge to Record 20.9% as FII Ownership ...
Sedentary Lifestyle and Its Hidden Health Risks
Market Commentary (closing) for 5th May 2026 by Baja...
BEL bags Rs 1,476 crore deal to make five Mobile Ele...
UIDAI, NFSU to boost cybersecurity, digital forensic...
Quote on Daily Gold Commentary for May 5th, 2026 by ...
